• 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • br Conflict of Interest Statement br A R


    Conflict of Interest Statement
    A.R. has received funding from Varian Medical Systems, Boehringer Ingelheim, Pfizer, and AstraZeneca. All other
    The Journal of Thoracic and Cardiovascular Surgery c Volume 157, Number 1 371
    Thoracic: Lung Cancer: Review Cao et al
    authors have nothing to disclose with regard to commercial support.
    1. Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol. 2009; 27:3290-6.
    2. Baba F, Shibamoto Y, Ogino H, Murata R, Sugie C, Iwata H, et al. Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size. Radiat Oncol. 2010;5:81.
    3. Jeppesen SS, Schytte T, Jensen HR, Brink C, Hansen O. Stereotactic body AMG 925 therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: an updated retrospective study on local failure and survival rates. Acta Oncol. 2013;52:1552-8.
    4. Palma D, Visser O, Lagerwaard FJ, Belderbos J, Slotman BJ, Senan S. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol. 2010;28:5153-9.
    5. Woody NM, Stephans KL, Marwaha G, Djemil T, Videtic GM. Stereotactic body radiation therapy for non-small cell lung cancer tumors greater than 5 cm: safety and efficacy. Int J Radiat Oncol Biol Phys. 2015;92:325-31.
    6. Nagata Y, Hiraoka M, Shibata T, Onishi H, Kokubo M, Karasawa K, et al. Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer: Japan clinical oncology group study JCOG0403. Int J Radiat Oncol Biol Phys. 2015;93:989-96.
    7. Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16:630-7.
    9. Meyers BF, Puri V, Broderick SR, Samson P, Keogan K, Crabtree TD. Lobectomy versus stereotactic body radiotherapy for stage I non-small cell lung cancer: post hoc analysis dressed up as level-1 evidence? J Thorac Cardiovasc Surg. 2015;150:468-71.
    10. Rosenbaum PR, Rubin DB. The central role of propensity score in observational studies for casual effects. Biometrika. 1983;70:41-55.
    12. AMG 925 Wells GS, O’Connell BD, Welch PJ, Losos V, Tugwell M. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: Accessed October 15, 2018.
    13. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
    14. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival end points. Stat Med. 1998;17:2815-34.
    15. Guyot P, Ades A, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.
    16. Paul S, Lee PC, Mao J, Isaacs AJ, Sedrakyan A. Long term survival with stereotactic ablative radiotherapy (SABR) versus thoracoscopic sublobar lung resection in elderly people: national population based study with propensity matched comparative analysis. BMJ. 2016;354:i3570.
    17. Smith BD, Jiang J, Chang JY, Welsh J, Likhacheva A, Buchholz TA, et al. Cost-effectiveness of stereotactic radiation, sublobar resection, and lobectomy for early non-small cell lung cancers in older adults. J Geriatr Oncol. 2015;6: 324-31.